A tailor-made reconstituted tumor microenvironment (TME) co-culture platform capable of combining tumor organoids of interest, fibroblasts and immune cells e.g. T cells, Monocytes, M1 and M2 macrophages.
This platform is well-suited for therapeutics targeting the TME including immunotherapy,TME specific drug delivery, fibroblast modulation, immune re-activation and recruitment.
Use our unique organoid co-culture platform to benefit from:
Our organoid co-culture platform is available to:
Organoids and fibroblasts can be genetically engineered to express your desired biomarker, immunotherapy target or to detect tumor organoid killing by (immune-) fluorescent imaging.
Tumor organoids are developed directly from patient tumors and matched healthy tissue using patented and exclusive HUB technology. Our well-characterized and ample patient-derived xenograft (PDX) collection is also available as an alternative source of human tumor tissue. PDX models allow additional tumor organoid development across more indications and to truly represent patient population diversity for biomarker identification and hypothesis generation.